A monoclonal antibody, nemolizumab is intended to treat adults with moderate-to-severe prurigo nodularis. Credit: Kwangmoozaa / Shutterstock. Galderma has reported that the randomised Phase III ...

Galderma has reported that the randomised Phase III OLYMPIA 1 trial, which evaluated the nemolizumab monotherapy in adult subjects with moderate-to-severe prurigo nodularis (PN), has achieved both ...

1 “These results, alongside the OLYMPIA 2 trial data, formed the basis of nemolizumab’s recent U.S. Food and Drug Administration approval for the treatment of adults with prurigo nodularis.

Full results from the phase III OLYMPIA 1 trial evaluating the efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis have been published in JAMA Dermatology ...

Prurigo nodularis (PN) is a chronic (long-term) skin condition that causes intense itching and firm bumps on the outer layer of the skin, known as nodules. As a result of the itching, some people ...

Sorry, your browser doesn't support embedded videos. “These results, alongside the OLYMPIA 2 trial data, formed the basis of nemolizumab’s recent U.S. Food and ...

Under the name Nemluvio ®, it was approved by the U.S. Food and Drug Administration (FDA) for the treatment of prurigo nodularis in adults in August 2024, becoming the first approved monoclonal ...

Galderma’s nemolizumab has been shown to improve the core signs and symptoms of prurigo nodularis, according to phase 3 results published in JAMA Dermatology. The 24-week OLYMPIA 1 trial evaluated the ...

WEDNESDAY, Nov. 27, 2024 (HealthDay News) -- Nemolizumab monotherapy leads to significant improvements in the signs and symptoms of moderate-to-severe prurigo nodularis (PN), according to a study ...